![]() |
產地 | 進口、國產 |
品牌 | 上海莼試 |
保存條件 | Store at -20 °C |
貨號 | CS10360 |
應用范圍 | WB=1:100-500 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 ICC=1:100-500 IF=1:100-500 |
CAS編號 | |
抗體名 | Anti-Prion protein PrP/CD230 |
克隆性 | |
靶點 | 詳見說明書 |
適應物種 | 詳見說明書 |
形態(tài) | 詳見說明書 |
宿主 | 詳見說明書 |
亞型 | IgG |
標識物 | 詳見說明書 |
濃度 | 1mg/1ml% |
免疫原 | KLH conjugated synthetic peptide derived from human Prion protein PrP/CD230 |
產品訂購信息:
英文名稱 Anti-Prion protein PrP/CD230
中文名稱 朊蛋白CD230抗體說明書
別 名 AltPrP; ASCR; atal familial insomnia; CD230; CD230 antigen; CJD; Creutzfeld Jakob disease; Gerstmann-Strausler-Scheinker syndrome; GSS; KURU; Major prion protein; PRIO_HUMAN.
濃 度 1mg/1ml
規(guī) 格 0.2ml/200μg
抗體來源 Rabbit
克隆類型 polyclonal
交叉反應 Human, Mouse, Rat, Horse
產品類型 一抗
研究領域 細胞生物 神經生物學 干細胞 細菌及 細胞表面分子
蛋白分子量 predicted molecular weight: 25kDa
性 狀 Lyophilized or Liquid
免 疫 原 KLH conjugated synthetic peptide derived from human Prion protein PrP/CD230
亞 型 IgG
純化方法 affinity purified by Protein A
儲 存 液 Preservative: 15mM Sodium Azide, Constituents: 1% BSA, 0.01M PBS, pH 7.4
朊蛋白CD230抗體說明書 產品應用 WB=1:100-500 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 ICC=1:100-500 IF=1:100-500
(石蠟切片需做抗原修復)
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
保存條件 Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
Important Note This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.
產品介紹 The function of PrP is still under debate. May play a role in neuronal development and synaptic plasticity. May be required for neuronal myelin sheath maintenance. May play a role in iron uptake and iron homeostasis (By similarity). Isoform 2 may act as a growth suppressor by arresting the cell cycle at the G0/G1 phase. Soluble oligomers are toxic to cultured neuroblastoma cells and induce apoptosis (in vitro).
Function : The function of PrP is still under debate. May play a role in neuronal development and synaptic plasticity. May be required for neuronal myelin sheath maintenance. May play a role in iron uptake and iron homeostasis (By similarity). Isoform 2 may act as a growth suppressor by arresting the cell cycle at the G0/G1 phase. Soluble oligomers are toxic to cultured neuroblastoma cells and induce apoptosis (in vitro).
Subunit : Monomer and homodimer. Has a tendency to aggregate into amyloid fibrils containing a cross-beta spine, formed by a steric zipper of superposed beta-strands. Soluble oligomers may represent an intermediate stage on the path to fibril formation. Copper binding may promote oligomerization. Interacts with GRB2, APP, ERI3/PRNPIP and SYN1. Mislocalized cytosolically exposed PrP interacts with MGRN1; this interaction alters MGRN1 subcellular location and causes lysosomal enlargement (By similarity). Interacts with KIAA1191.
Subcellular Location : Cell membrane. Golgi apparatus and Cytoplasm. Nucleus. Accumulates outside the secretory route in the cytoplasm, from where it relocates to the nucleus.
Isoform 2 is sumoylated by SUMO1.
DISEASE : Note=PrP is found in high quantity in the brain of humans and animals infected with neurodegenerative diseases known as transmissible spongiform encephalopathies or prion diseases, like: Creutzfeldt-Jakob disease (CJD), fatal familial insomnia (FFI), Gerstmann-Straussler disease (GSD), Huntington disease-like type 1 (HDL1) and kuru in humans; scrapie in sheep and goat; bovine spongiform encephalopathy (BSE) in cattle; transmissible mink encephalopathy (TME); chronic wasting disease (CWD) of mule deer and elk; feline spongiform encephalopathy (FSE) in cats and exotic ungulate encephalopathy (EUE) in nyala and greater kudu. The prion diseases illustrate three manifestations of CNS degeneration: (1) infectious (2) sporadic and (3) dominantly inherited forms. TME, CWD, BSE, FSE, EUE are all thought to occur after consumption of prion-infected foodstuffs.
Defects in PRNP are the cause of Creutzfeldt-Jakob disease (CJD) [MIM:123400]. CJD occurs primarily as a sporadic disorder (1 per million), while 10-15% are familial. Accidental transmission of CJD to humans appears to be iatrogenic (contaminated human growth hormone (HGH), corneal transplantation, electroencephalographic electrode implantation, etc.). Epidemiologic studies have failed to implicate the ingestion of infected annimal meat in the pathogenesis of CJD in human. The triad of microscopic features that characterize the prion diseases consists of (1) spongiform degeneration of neurons, (2) severe astrocytic gliosis that often appears to be out of proportion to the degree of nerve cell loss, and (3) amyloid plaque formation. CJD is characterized by progressive dementia and myoclonic seizures, affecting adults in mid-life. Some patients present sleep disorders, abnormalities of high cortical function, cerebellar and corticospinal disturbances. The disease ends in death after a 3-12 months illness.
Defects in PRNP are the cause of fatal familial insomnia (FFI) [MIM:600072]. FFI is an autosomal dominant disorder and is characterized by neuronal degeneration limited to selected thalamic nuclei and progressive insomnia.
Defects in PRNP are the cause of Gerstmann-Straussler disease (GSD) [MIM:137440]. GSD is a heterogeneous disorder and was defined as a spinocerebellar ataxia with dementia and plaquelike deposits. GSD incidence is less than 2 per 100 million live births. Defects in PRNP are the cause of Huntington disease-like type 1 (HDL1) [MIM:603218]. HDL1 is an autosomal dominant, early onset neurodegenerative disorder with prominent psychiatric features.
Defects in PRNP are the cause of kuru (KURU) [MIM:245300]. Kuru is transmitted during ritualistic cannibalism, among natives of the New Guinea highlands. Patients exhibit various movement disorders like cerebellar abnormalities, rigidity of the limbs, and clonus. Emotional lability is present, and dementia is conspicuously absent. Death usually occurs from 3 to 12 month after onset.
Defects in PRNP are the cause of spongiform encephalopathy with neuropsychiatric features (SENF) [MIM:606688]; an autosomal dominant presenile dementia with a rapidly progressive and protracted clinical course. The dementia was characterized clinically by frontotemporal features, including early personality changes. Some patients had memory loss, several showed aggressiveness, hyperorality and verbal stereotypy, others had parkinsonian symptoms.
Prion diseases, or transmissible spongiform encephalopathies (TSEs), are manifested as genetic, infectious or sporadic, lethal neurodegenerative disorders involving alterations of the prion protein (PrP). Characteristic of prion diseases, cellular PrP (PrPc) is converted to the disease form, PrPSc, through alterations in the protein folding conformations. PrPc is constitutively expressed in normal adult brain and is sensitive to proteinase K digestion, while the altered PrPSc conformation is resistant to proteases, resulting in a distinct molecular mass after PK treatment. Consistent with the transient infection process of prion diseases, incubation of PrPc with PrPSc both in vitro and in vivo produces PrPc that is resistant to protease degradation. Infectious PrPSc is found at high levels in the brains of animals affected by TSEs, including scrapie in sheep, BSE in cattle and Cruetzfeldt-Jakob disease in humans.
Similarity : Belongs to the prion family.
Database links : UniProtKB/Swiss-Prot: P04156.1
25(OH)D3/25 HVD3(Human 25-Dihydroxy vitamin D3)ELISA Kit 人25羥基維生素D3Multi-class antibodies規(guī)格: 48T
Anti-MMP-16 基質金屬蛋白酶-16抗體Multi-class antibodies規(guī)格: 0.1ml
Rhesus antibody Rh Interferon alpha 6 干擾素α6抗體 規(guī)格 0.2ml
anti-HAV(Human anti-hepatitis A virus IgG antibody) ELISA Kit 人IgG抗體 96T
RNA polymerase II 英文名稱: RNA聚合酶II抗體 0.2ml
Alx1 英文名稱: 軟骨蛋白1抗體 0.1ml
Anti-MMP-16 基質金屬蛋白酶-16抗體Multi-class antibodies規(guī)格: 0.1ml
NO(Mouse nitric oxide) ELISA Kit 小鼠Multi-class antibodies規(guī)格: 48T
Anti-Chloramphenicol/FITC 熒光素標記抗氯霉素抗體IgGMulti-class antibodies規(guī)格: 0.2ml
Rhesus antibody Rh Dog IgM/Cy7 Cy7標記的兔抗犬IgM抗體 規(guī)格 0.1ml
Rat IgM/RBITC 羅丹明標記大鼠IgM 0.3ml
Lamin B 英文名稱: 核纖層蛋白B抗體(細胞核膜標志物) 0.1ml
磺胺類多殘留快速檢測卡 50T/盒 蜂蜜、奶、奶粉
Anti-Chloramphenicol/FITC 熒光素標記抗氯霉素抗體IgGMulti-class antibodies規(guī)格: 0.2ml
Anti-IL-17D/IL-27/FITC 熒光素標記白介素-17D抗體IgGMulti-class antibodies規(guī)格: 0.2ml
Anti-RAMP-1/FITC 熒光素標記受體活性調制蛋白1抗體IgGMulti-class antibodies規(guī)格: 0.2ml
Rhesus antibody Rh APBB1/Fe65 protein 鐵蛋白Fe65抗體 規(guī)格 0.1ml
Rabbit Anti-rat IgG/Cy7 Cy7標記的兔抗大鼠IgG 0.1ml
GIMAP2 英文名稱: GTP酶IMAP家族成員2抗體 0.2ml
Rhesus antibody Rh Rabbit Anti-human IgM/Cy7 Cy7標記的兔抗人IgM 規(guī)格 0.1ml
Anti-RAMP-1/FITC 熒光素標記受體活性調制蛋白1抗體IgGMulti-class antibodies規(guī)格: 0.2ml
大鼠抗激素/加壓素/精酸加壓素(ADH/VP/AVP)ELISA試劑盒 ,英文名: ADH/VP/AVP ELISA Kit
人樣生長因子結合蛋白3(IGFBP-3)ELISA檢測試劑盒Humaninsulin-likegrowthfactorsbindingprotein3,IGFBP-3ELISAKit 96T/48T
新城疫病毒(NDV)核酸檢測試劑盒(PCR-熒光探針法) 48T
CLIAKitforNP-Y(MouseneuropeptideY)ELISAKit小鼠神經肽Y規(guī)格:48T/96T
體外非細胞系統(tǒng)細胞色素P450亞酶CYP2B(EFC)活性熒光定量檢測試劑盒20次
ELISAKitα-SCA人α橫紋肌肌動蛋白規(guī)格:48T/96T
大鼠白介素22受體α2(IL2Rα2)ELISA試劑盒 ,英文名: IL2Rα2 ELISA Kit
Human beta lactose protein aibody IgGELISA Kit 人β乳糖蛋白抗體IgGELISA試劑盒
Sophorajaponicaagglinin,SJAELISAKit 槐凝集素(SJA)ELISA試劑盒 96T/48T 進口分裝
CLIAKitforCLA(HumanCollagenaoaibody)ELISAKit人抗膠原蛋白抗體規(guī)格:48T/96T
細胞脂酰輔酶A合成酶(ACYLCOASYHETASE)總活性酶連續(xù)循環(huán)比色法定量檢測試劑盒20次
RatCalcitonin,CTELISAKit大鼠降鈣素(CT)ELISA試劑盒規(guī)格:96T/48T
朊蛋白CD230抗體說明書 大鼠成纖維細胞生長因子11(FGF11)ELISA試劑盒 ,英文名: FGF11 ELISA Kit
Human XC chemokine receptor 1 (XCR1) ELISA Kit 人XC趨化因子受體1(XCR1)ELISA試劑盒
RatCarboxyterminalpropeptideoftypeⅠprocollagen,PⅠCPELISAKit 大鼠Ⅰ型前膠原羧基端肽(PⅠCP)ELISA試劑盒 96T/48T 進口分裝
CLIAKitforCr(MouseCrosslaps)ELISAKit小鼠骨膠原交聯(lián)規(guī)格:48T/96T
細胞緊張素Ⅰ轉化酶2(ACE2)活性熒光共振能量轉移法(FRET)定量檢測試劑盒20次
RatCystatinC,Cys-CELISAKit大鼠半胱氨酸蛋白酶抑制劑/胱抑素C(Cys-C)ELISA試劑盒規(guī)格:96T/48T
抗體的生物素化標記實驗要點:
1. 朊蛋白CD230抗體說明書 如在反應混合液中有疊氮鈉或游離氨基存在,會抑制標記反應。因此,蛋白質在反應前要對 0.1mol/L碳酸氫鈉緩沖液或0.5mol/L硼酸緩沖液充分透析;
2.所用的NHSB及待生物素化蛋白質之間的分子比按蛋白質表面的ε-氨基的密度會有所不同,選擇不當則影響標記的效率,應先用幾個不同的分子比來篩選最適條件;
3.用NHSB量過量也是不利的,抗原的結合位點可能因此被封閉,導致抗體失活;
4.由于抗體的氨基不易接近可能造成生物素化不足,此時可加入去污劑如 Triton x-100, Tween20等;
5.當游離ε-氨基(賴氨酸殘基的氨基)存在于抗體的抗原結合位點時,或位于酶的催化位點時,生物素化會降低或損傷抗體蛋白的結合力或活性;
6.生物素還可能與不同的功能基團,如羰基、氨基、巰基、異咪唑基及苯酚基,也可與糖基共價結合;
7.交聯(lián)反應后,應充分透析,否則,殘余的生物素會對生物素化抗體與親和素的結合產生競爭作用;
8.在細胞的熒光標記實驗中,中和親和素的本底低,但由于鏈霉親和素含有少量正電荷,故對某些細胞可導致高本底。
抗體的鑒定:
1)朊蛋白CD230抗體說明書 抗體的效價鑒定:不管是用于診斷還是用于,制備抗體的目的都是要求較高效價。不同的抗原制備的抗體,要求的效價不一。鑒定效價的方法很多,包括有試管凝集反應,瓊脂擴散試驗,酶聯(lián)免疫吸附試驗等。常用的抗原所制備的抗體一般都有約成的鑒定效價的方法,以資比較。如制備抗抗體的效價,一般就采用瓊脂擴散試驗來鑒定。
2)抗體的特異性鑒定:抗體的特異性是指與相應抗原或近似抗原物質的識別能力??贵w的特異性高,它的識別能力就強。衡量特異性通常以交叉反應率來表示。交叉反應率可用競爭抑制試驗測定。以不同濃度抗原和近似抗原分別做競爭抑制曲線,計算各自的結合率,求出各自在IC50時的濃度,并按公式計算交叉反應率。
如果所用抗原濃度IC50濃度為pg/管,而一些近似抗原物質的IC50濃度幾乎是無窮大時,表示這一抗血清與其他抗原物質的交叉反應率近似為0,即該血清的特異性較好。
3)抗體親和力:是指抗體和抗原結合的牢固程度。親和力的高低是由抗原分子的大小,抗體分子的結合位點與抗原決定簇之間立體構型的合適度決定的。有助于維持抗原抗體復合物穩(wěn)定的分子間力有氫鍵,疏水鍵,側鏈相反電荷基因的庫侖力,范德華力和空間斥力。親和力常以親和常數(shù)K表示,K的單位是L/mol??贵w親和力的測定對抗體的篩選,確定抗體的用途,驗證抗體的均一性等均有重要意義。